



Health

South Eastern Sydney
Local Health District

ClinTrial Refer – a Mobile App for IOS and android platforms to connect patients and haematologists with local clinical research trials.

Roslyn Ristuccia (St George/ Sutherland Hospitals)
Admir Huseincehajic (Concord Repatriation General Hospital)
Haematology Clinical Research Unit Managers

Judith Trotman (Concord Repatriation General Hospital)
Xavier Badoux (St George/ Sutherland Hospitals)
Haematologists

On behalf of the Haematology Clinical Research Network, NSW/ACT

Introduction

- There are significant challenges recruiting patients to haematology trials:

Rarity and low incidence of blood disease

Geographical Challenges

Cost- can't run all studies at all site

Knowledge Management- what trials and where?

- Patient referral between sites gives patients all treatment options available.

Introduction

- NSW Haematology Network of clinical trials co-ordinator staff founded in 2006
 - Decided to develop an App to facilitate referrals, and together with Haematologists, developed specifications for ClinTrial Refer
 - Launched in May
 - Available to download from iTunes and Google Play for free
 - Easy to use


In the fast moving world of exciting new targeted therapies for blood cancers in particular, **ClinTrial Refer** helps Haematologists find an appropriate trial for their patients with an easy to navigate list across a broad spectrum of haematological malignancies.



User can narrow down the search by Disease, Location, Trial Status and Sponsor.

ClinTrial Refer

Haematology NSW



Search for a trial using one or more filters

Disease	>	⊗
Locations	>	⊗
Trial Status	>	⊗
Sponsor	>	⊗


Search **Clear all**

Q

Navigate through a broad spectrum of Haematological malignancies

The screenshot shows the ClinTrial Refer app interface. At the top, there is a blue header with the text "ClinTrial Refer" and a white banner with "Haematology NSW". Below this is the NSW Government Health logo. A search prompt reads "Search for a trial using one or more filters". A filter menu is open, showing "Disease" selected. A dropdown menu is displayed, listing the following malignancies: Leukaemia-All Trials, Leukaemia-Chronic Lymphocytic (CLL), Leukaemia-Chronic Myeloid (CML), Lymphoma-Diffuse Large B Cell (DLBCL), Lymphoma-Follicular (FL), Lymphoma-Hodgkins, and Lymphoma-Non-Hodgkins (NHL). The interface also shows partial labels for "Location", "Trial S", and "Spon" on the left side of the filter menu.

Select Location of interest, usually closest to patients home



For example, if your patient has Diffuse Large B-Cell Lymphoma, you can select the Disease and search all available trials for DLBCL

The screenshot shows the 'ClinTrial Refer' app interface. At the top, there is a blue header with a help icon and the text 'ClinTrial Refer'. Below this is a banner for 'Haematology NSW' with a background image of red blood cells. The NSW Government Health logo is centered below the banner. A search instruction reads 'Search for a trial using one or more filters'. Below this is a list of four filter categories, each with a right-pointing chevron and a close button (an 'x' in a circle): 'Lymphoma-Diffuse Large B Cell (DLBCL)', 'Concord Hospital', 'Trial Status', and 'Sponsor'. At the bottom of the filter list are two buttons: a green 'Search' button and a blue 'Clear all' button. A search bar with a magnifying glass icon is located at the very bottom of the screen.

Click "Search" button and you should see all currently recruiting DLBCL trials

Back Search Results - 3 Trials

- ALLG NHL24 PCNSL**
Rituximab in Primary CNS Lymphoma >
- ALLG NHL25 REMARC**
Double blind randomized phase III study of Lenalidomide (Revlimid) maintenance versus placebo in responding elderly patients with DLBCL and treated with R-CHOP in first line. >
- ALLG Tissue Bank**
AMP Leukaemia and Lymphoma Tissue Bank: A joint research initiative of ALLG and the Leukaemia Foundation >

Whilst every effort is made to ensure the accuracy and completeness of this information, please contact the relevant location for current advice and referral information. The information on these pages cannot be guaranteed. Patients should discuss their suitability for any trial with their own doctor.

If a patient with DLBCL is interested in participating in the ALLG REMARC study...

Back Trial Details Email

ALLG NHL25 REMARC
Double blind randomized phase III study of Lenalidomide (Revlimid) maintenance versus placebo in responding elderly patients with DLBCL and treated with R-CHOP in first line.

Populations
CD20+ Diffuse Large B-Cell lymphoma- responding elderly patients

Trial Status ✓ Active

Trial Registration Number
ACTRN12611000085976 Copy TRN

[▶ Australian New Zealand Clinical Trials Registry](#) [▶ ClinicalTrials.gov](#)

Sponsor
ALLG

Phase
Phase III Inclusion Criteria
Exclusion Criteria

Locations Available Locations ▼

Whilst every effort is made to ensure the accuracy and completeness of this information, please contact the relevant location for current advice and referral information. The information on these pages cannot be guaranteed. Patients should discuss their suitability for any trial with their own doctor.

On ClinTrial Refer the clinician can view Inclusion...

Back **Trial Details** **Email**


ALLG NHL25 REMARC
Double blind randomized phase III study of Lenalidomide (Revlimid) maintenance versus placebo in responding elderly patients with DLBCL and treated with R-CHOP in first line.

Populations
CD20+ Diffuse Large B-Cell lymphoma, responding elderly patients

Back

For patients registered at the time of initial diagnosis: 1. Patient with histologically proven CD20+ diffuse large B-cell lymphoma (DLBCL) (WHO classification 2008) including clinical subtypes (primitive mediastinal, intravascular, etc.). Patients with De Novo Transformed DLBCL from low grade lymphoma (Follicular, other...) may also be included. Patients with DLBCL associated with small cell infiltration in bone marrow may also be included • Or CD20+ B-cell lymphoma with intermediate features between DLBCL and Burkitt or with intermediate features between DLBCL and classical Hodgkin lymphoma • Or CD20+ Follicular lymphoma grade 3B • Or CD20+ Aggressive B-cell lymphoma unclassifiable 2. Previously untreated with chemo- or radiotherapy For patients registered after response evaluation to first line treatment with R-CHOP: 1. Patient with histologically proven CD20+ diffuse large B-cell lymphoma (DLBCL) (WHO classification 2008) including clinical subtypes (primitive mediastinal, intravascular, etc.). Patients with De Novo Transformed DLBCL from low grade lymphoma (Follicular, other...) may also be included. Patients with DLBCL associated with small cell infiltration in bone marrow may also be included • Or CD20+ B-cell lymphoma with intermediate features between DLBCL and Burkitt or with intermediate features between DLBCL and classical Hodgkin lymphoma • Or CD20+ Follicular lymphoma grade 3B • Or CD20+ Aggressive B-cell lymphoma unclassifiable 2. Have reached a CR or PR (Cheson 2007) after

... and Exclusion Criteria to screen the patient for eligibility



ALLG NHL25 REMARC
Double blind randomized phase III study of Lenalidomide (Revlimid) maintenance versus placebo in responding elderly patients with DLBCL and treated with R-CHOP in first line.

Populations
CD20+ Diffuse Large B-Cell lymphoma, responding elderly patients

Back

For all patients: 1. Any other histological type of lymphoma, Burkitt included. 2. Any history of treated or non-treated small B-cell lymphoma 3. Central nervous system or meningeal involvement by lymphoma 4. Contraindication to any drug contained in the chemotherapy regimen For example: cardiac contra-indication to anthracyclines (impaired Left Ventricular Function defined by LVEF < 50%) neurological contra-indication to vincristine (peripheral neuropathy of WHO grade = 2). 5. Myocardial infarction in the last 3 months or unstable coronary disease or uncontrolled chronic symptomatic congestive heart insufficiency NYHA III - IV 6. Uncontrolled hypertension 7. Uncontrolled diabetes mellitus as defined by the investigator 8. Active systemic infection requiring treatment. 9. Previously known HIV positive serology 10. Active hepatitis B or C 11. Prior history of malignancies other than lymphoma within 3 years (except for complete resection of basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of breast or cervix. Patients previously diagnosed with prostate cancer are eligible if (1) their disease was T1-T2a, N0, M0, with a Gleason score =7, and a prostate specific antigen (PSA) =10 ng/mL prior to initial therapy, (2) they had definitive curative therapy (ie, prostatectomy or radiotherapy) =2 years before Day 1 of Cycle 1, and (3) at a minimum 2 years following therapy they had no clinical evidence of prostate cancer, and their PSA was undetectable if they underwent prostatectomy or < 1 ng/mL if they did not undergo

... then can identify which hospitals in NSW can offer the study.

Back Trial Details Email

ALLG NHL25 REMARC
Double blind randomized phase III study of Lenalidomide (Revlimid) maintenance versus placebo in responding elderly patients with DLBCL and treated with R-CHOP in first line.

Populations
CD20+ Diffuse Large B-Cell lymphoma- responding elderly patients

Trial Status ✓ Active

Trial Registration Number ACTRN12611000085976 Copy TRN

[Australian New Zealand Clinical Trials Register](#)

Sponsor
ALLG

Phase
Phase III


Locations Available Locations ▼


- Calvary Mater Newcastle...
- Canberra Hospital
- Concord Hospital
- St George/Sutherland Hos...


Whilst every effort is made to ensure the accuracy and completeness of this information, please contact the relevant location for current advice and referral information. The information on these pages cannot be guaranteed. Patients should discuss their suitability for any trial with their own doctor.


They can contact the responsible person for more details and/or possible enrolment, including emailing them directly using the email icon in the top right


Back Location Details Email


 **Location:**
Concord Hospital

 **Contact Name:**
Admir Huseincehajic

 **Contact Email:**
CRGHHaem.CRU@sswahs.nsw.gov.au

 **Contact Telephone:**
02 9767 6348

 **Web URL:**
http://connectclinical.com.au/site/cc/Concord-Hospital_Haematology

 **NSW**
GOVERNMENT | Health

ClinTrial Refer
Haematology NSW

To learn more about the study,
the ANZ Clinical Trials Registry Trial Registration Number (TRN) can be copied

Back Trial Details Email

ALLG NHL25 REMARC
Double blind randomized phase III study of Lenalidomide (Revlimid) maintenance versus placebo in responding elderly patients with DLBCL and treated with R-CHOP in first line.

Populations
CD20+ Diffuse Large B-Cell lymphoma- responding elderly patients

Trial Status ✓ Active

Trial Registration Number Copy TRN
ACTRN12611000085976

[▶ Australian New Zealand Clinical Trials Registry](#) [▶ ClinicalTrials.gov](#)


Sponsor
ALLG

Phase
Phase III Inclusion Criteria
Exclusion Criteria

Locations Available Locations ▼

Whilst every effort is made to ensure the accuracy and completeness of this information, please contact the relevant location for current advice and referral information. The information on these pages cannot be guaranteed. Patients should discuss their suitability for any trial with their own doctor.

... and pasted directly on to the ANZ Clinical Trial Registry website



... and all details can be viewed...



iPad 7:10 PM 9%

www.anzctr.org.au/Trial/Registration/TrialReview.as Search

ANZCTR Assassin's Creed Rearmed | Facebook

Trial from ANZCTR

Trial ID	ACTRN1261100085976
Trial Status:	Registered
Date Submitted:	23/12/2010
Date Registered:	24/01/2011
	Prospectively registered

Page 1

Public title	Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With Diffuse Large B cell Lymphoma (DLBCL) and Treated With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)
Study title in 'Participant-Intervention-Comparator- Outcome (PICO)' format	Double blind randomized phase III study of Lenalidomide (Revlimid Registered Trademark) maintenance versus Placebo in responding elderly patients with diffuse large B cell lymphoma (DLBCL) and treated with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in first line
Secondary ID [1]	Clinical trials.gov NCT01122472
UTN	
Trial acronym	REMARC

Page 2

Health condition(s) or problem(s) studied:

Diffuse large B cell lymphoma (DLBCL) in elderly patients

Condition category:	Condition code:
Cancer	Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma

Page 3

Descriptions of intervention(s) / exposure	25mg daily lenalidomide for 21 days of a 28 day cycle of maintenance therapy for up to 26 cycles. Lenalidomide is an oral tablet.
Intervention Code:	Treatment: drugs
Comparator / control treatment	placebo oral tablet contains the excipients used for the drug product without the active ingredient and it conforms to the colour and size for blinded study. It is taken daily for 21 days of a 28 day cycle of maintenance therapy for up to 26 cycles.
Control group	Placebo


Page 4

Primary Outcome:	to determine the benefit estimated by the progression-free survival associated with lenalidomide maintenance compared to placebo in responding patients treated with R-CHOP for diffuse large B-cell lymphoma. Progression will be measured by tests such as CT scan, PET scan and Bone Marrow examination.
Timepoint:	3 years after the last patient is randomised or the first date of disease progression or relapse

Outcome Referrals- a 300% increase in referrals since the App launch in May



Snapshot of usage - Sep 2013 - user engagement- 91% of NSW users are repeat users



ClinTrial Refer consumer groups

You are here: [Home](#) > [ClinTrial Refer](#)

ClinTrial Refer

Lymphoma Australia, CEO Sharon Millman recently attended the launch of a new free app titled Clin Trials Refer at Concord Hospital. Clin Trials Refer supplies a current listing of active and pending haematology clinical research trials in NSW and ACT. The app will be updated monthly, with trial location sites, and contact details for the trial you are interested in knowing more about.

Lymphoma Australia has found from speaking with many patients that the process of finding a Lymphoma trial relevant to your subtype can be a very confusing and time consuming process. According to Lymphoma Australia CEO, Sharon Millman, this app is simple to use and the information can be easily discussed with your treating doctor.

Clin Trials Refer is the result of the tireless work of the development team at the Haematology Clinical Research Network NSW. ([Read more from the Media Release HERE](#))



ClinTrial Refer Launch with Lymphoma Australia



New App on iPhone and iPad

Now Available from the App Store ([Click Here](#)) Screenshots of the app Below.




Lymphoma Australia website advises its consumers to use the App.

Lessons learned

- Patients will travel to other sites for life-lengthening treatments
- Haematologists will refer to other sites
- That a strong networked partnership between haematologists, research co-ordinators and participants can enable patients to access best available treatments over the state
- That innovation can help partnerships

Currently the App is specific for Haematology in NSW and the ACT but can be adopted to any clinical research portfolio both in Australia and internationally



A microscopic view of numerous red blood cells (erythrocytes) in a fluid medium. The cells are biconcave discs, appearing as reddish-orange spheres with a darker center. They are scattered across the frame, with some in sharp focus and others blurred in the background. The overall color palette is warm, dominated by reds and oranges.

Haematology NSW